(redirected from Hormone-Sensitive Prostate Cancer)
HSPCHormone-Sensitive Prostate Cancer
HSPCHealth Science Planning Consultants (Australia)
HSPCHigh School Preparation Course (various universities)
HSPCHigh School Policy Center
HSPCHuman Services Planning Council
HSPCHigh Speed Passenger Craft (ship)
HSPCHeat Sterilizable Potting Compound
References in periodicals archive ?
Metastatic castration-sensitive prostate cancer (CSPC), also referred to as metastatic hormone-sensitive prostate cancer (HSPC) in literature, refers to prostate cancer that still responds to testosterone suppression therapy.
This EC approval is a major step forward for men living with prostate cancer across Europe and offers patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer a new treatment option," said Dr Ivo Winiger-Candolfi, oncology solid tumour therapy area lead for Janssen Europe, Middle East and Africa.
In light of conflicting opinion on the ideal goal for suppression of serum testosterone in men with advanced cancer, we conducted a survey of Canadian urologists, uro-oncologists, and radiation oncologists to gain a better understanding of their testosterone monitoring practices when managing men with hormone-sensitive prostate cancer.
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)
Janssen-Cilag International NV today announced additional data from the pivotalLATITUDE clinical trial, which showed that treatment with Zytiga (abiraterone acetate) plus prednisone, in combination with androgen deprivation therapy (ADT), demonstrated clinically meaningful and statistically significant improvements in a range of patient reported outcomes (PRO) in patients with newly diagnosed, high-risk, metastatic hormone-sensitive prostate cancer (mHSPC), compared to ADT alone.
Declines in quality of life with early docetaxel treatment may be offset by long-term gains for men with metastatic hormone-sensitive prostate cancer
3,4) The CHAARTED study, which showed an OS benefit of docetaxel in metastatic, hormone-sensitive prostate cancer, (5) also included global measures of QOL that account for disease-related symptoms, as well as treatment-related symptoms.
Medivation and Astellas have built a robust development program for XTANDI, including two Phase 3 studies in non-metastatic prostate cancer and another Phase 3 study in hormone-sensitive prostate cancer.
A new Phase III study ARASENS will evaluate the compound in combination with standard androgen deprivation therapy (ADT) and the chemotherapy docetaxel in men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are starting first line hormone therapy.
Taken together, these data suggest that the addition of docetaxel to standard of care should be considered standard care for men with M1 hormone-sensitive prostate cancer who are starting treatment for the first time.
While there is agreement about the need for androgen suppression in hormone-sensitive prostate cancer, optimal testoster-one levels on ADT remains a matter of debate.